Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEurocell Regulatory News (ECEL)

Share Price Information for Eurocell (ECEL)

Share Price is delayed by 15 minutes
Get Live Data
106.00    -3.00 (-2.75%)
Bid:
105.00
Ask:
107.00
Spread: 2.00 (1.905%)
Market Cap: £104.46m
ECEL Live PriceLast checked at - London Stock Exchange

Intraday Eurocell Share Chart

Year End Trading Update

21 Jan 2022 07:00

RNS Number : 1611Z
Eurocell plc
21 January 2022
Β 

21 January 2022

EUROCELL PLC

("Eurocell" or the "Group")

Β 

Year End Trading Update - Positive Finish to 2021, Strong Platform for 2022

Β 

Eurocell plc, the market leading, vertically integrated UK manufacturer, recycler and distributor of innovative window, door and roofline PVC products, provides the following update for the year ended 31 December 2021.

Β 

Summary

The strong sales performance previously announced for the ten months to 31 October continued through to the end of the year, supported by good underlying demand in our markets. We have taken effective action to mitigate ongoing cost inflation and supply chain pressures. As a result, we now believe profit before tax for the full year will be slightly ahead of current market expectations(1).

Β 

Trading Performance

Group sales for the six months to 31 December were up 23% compared to 2019 and 7% compared to 2020, with the latter reflecting a very strong second half in that year. For the year ended 31 December 2021, sales were Β£343 million, up 23% compared to 2019 and 33% compared to 2020. Divisional growth rates were as follows:

Β 

Sales growth

6 months to 31 Dec 2021

12 monthsto 31 Dec 2021

6 months to 31 Dec 2021

12 monthsto 31 Dec 2021

vs 2019

vs 2020

Total Group

23%

23%

7%

33%

Profiles Division

24%

22%

14%

41%

Building Plastics Division

21%

24%

2%

28%

Β 

Whilst demand in the repair, maintenance and improvement (RMI) market has moderated from the unprecedented levels experienced in H2 2020 and H1 2021, this sector remains strong and customer demand levels are good going into 2022. We believe we are also continuing to take market share.

Β 

Group sales growth for the year ended 31 December of 23% compared to 2019 includes:

Β· Profiles up 22% - good contributions from trade fabricators, who are substantially focused on the RMI market, and another very strong performance from Vista doors. New build enjoyed improved sales in the second half, as the house builders focused on achieving year end completion targets

Β· Building Plastics up 24% - good performance across our full range of own-manufactured products and traded goods, including more than 150% growth in outdoor living products, supported by a consistently strong order book. We opened 12 new branches in the year, 4 of which are the new larger format, taking the total estate to 219 sites

Β 

We have continued to secure the raw materials we require and we expect past constraints to ease over the coming months. We have mitigated raw material cost inflation with selling price increases and surcharges, with price inflation becoming a larger component of sales growth as the year progressed. We are also pleased to report that the actions we took in H2 2021 to secure more labour have ensured that we have the staff necessary to operate efficiently and support our growth aspirations.

Β 

Our market-leading recycling plants supported continuity of supply of resin in tight markets, whilst continuing to improve the proportion of recycled material used in our primary extrusion operations. These plants supplied 27% of our raw material consumption for the year (2020: 25%), driving significant cost and carbon savings compared to the use of virgin material.

Β 

Net debt at 31 December 2021 on a pre-IFRS 16 basis was c.Β£11 million (31 December 2020: Β£10 million), which includes the substantial impact of inflation on the components of working capital.

Β 

New Warehouse and Manufacturing Capacity Expansion

As previously reported, fit-out of our new state-of-the-art warehouse is now complete. As well as being central to increasing capacity, the facility is key to delivering further improvements in operational efficiencies as the new plant, systems and processes become embedded, and we are optimistic that operating performance will exceed our original expectations.

Β 

The 2021 manufacturing capacity expansion, including 5 new extrusion lines, together with the associated mixing plant upgrade and tooling, is also now complete. We plan to add a further 5 lines in 2022. Together, these investments increase extrusion capacity by more than 15%, thereby enabling future sales and market share growth.

Β 

Notice of Results

As previously announced, we expect to publish our results for the year ended 31 December 2021 on 18 March 2022.

Β 

Β 

Notes

(1) Eurocell calculated analyst consensus profit before tax forecast for 2021 of Β£26.5 million.

Β 

Enquiries:

Mark Kelly, Chief Executive Officer

+44 (0) 1773 842 105

Michael Scott, Chief Financial Officer

+44 (0) 1773 842 140

Ben Foster (Teneo)

+44 (0) 777 624 0806

Β 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTVBLFLLFLEBBQ
Date   Source Headline
18th May 20264:00 pmRNSDirector/PDMR Shareholding
14th May 20261:49 pmRNSResult of AGM
14th May 20267:00 amRNSTrading Update
1st May 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSLeadership Update - CFO Appointment
15th Apr 20267:00 amRNSPublication of 2025 Annual Report & Notice of AGM
23rd Mar 202610:15 amRNSDirector/PDMR Shareholding
19th Mar 202610:30 amRNSDirector/PDMR Shareholding
19th Mar 20267:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2025
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSTransaction in Own Shares - Buyback Complete
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20261:00 pmRNSDirectorate changes
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSDirector/PDMR Shareholding
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTransaction in Own Shares
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSYear End Trading Update
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20254:00 pmRNSPurchase of Shares via Employee Benefit Trust
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.